Multinational Association of Supportive Care in Cancer International Symposium

Dorothy M. K. Keefe, MD, FRACP, past president, MASCC, director, SA Cancer Service, professor of cancer medicine, University of Adelaide, Australia, discusses the role of supportive care in personalized medicine.

Bernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses the utility of rolapitant for preventing chemotherapy-induced nausea and vomiting (CINV).

Aprepitant is significantly more effective than a comparator placebo-added regimen in preventing CINV in children, with benefits seen across all phases of treatment.

Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline with placebo in patients with non-small cell lung cancer.

A single oral dose of rolapitant was found to be effective, safe, and long-lasting for the prevention of CINV in patients whose cancer was being treated with either highly or moderately emetogenic chemotherapy.

Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based moderately emetogenic chemotherapy when compared with a longer duration of dexamethasone.

A treatment intended to control chemotherapy-induced nausea and vomiting that combines netupitant and palonosetron demonstrated superior activity in complete response rates over oral palonosetron monotherapy.

For the prevention of nausea and vomiting after the first day of cisplatin-based chemotherapy, both aprepitant and metoclopramide when used in combination with dexamethasone were found to be similarly effective.

Declan Walsh, MSc, FACP, FRCP, director, 2014 MASCC/ISOO International Symposium, discusses the under-diagnosis of malnutrition in palliative medicine.

Alex Molasiotis, RN, PhD, discusses the results of a pilot feasibility study looking at inspiratory muscle training for the management of breathlessness in patients with lung cancer.

Fausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis.

Dorothy M. K. Keefe, MD, FRACP, past president, MASCC, director, SA Cancer Service, professor of cancer medicine, University of Adelaide, discusses links between toxicities associated with anticancer drugs.

Haralambos Raftopoulos, MD, associate professor, Hofstra North Shore-LIJ School of Medicine, discusses pulmonary toxicity with EGFR tyrosine kinase inhibitors (TKIs).

Ã…ge Schultz, DVM, PhD, executive director, Multinational Association of Supportive Care in Cancer (MASCC), discusses pain management and the cost of supportive care medicine.

Kathleen M. Foley, MD, from Memorial Sloan-Kettering Cancer Center, on the history and future goals for cancer pain management.

Dr. Kathleen Foley, from Memorial Sloan-Kettering Cancer Center, Addresses the Importance of Palliative Care

Dr. Paul J. Hesketh, from Lahey Clinic Medical Center, on Developing Guidelines and Protocols

Dr. Michael S. Ewer, from The University of Texas MD Anderson Cancer Center, on Supportive Care

Dr. Richard Gralla, from Quality of Life Research Associates, on Future Advances in chemotherapy-induced nausea and vomiting Prevention

Carrie Stricker, PhD, RN, from Abramson Cancer Center, on Barriers to Adopting Triple Therapy

Steven M. Grunberg, MD, University of Vermont, on Barriers to Providing Effective Supportive Care for Patients with Cancer.

Paul J. Hesketh, MD, from Lahey Clinic Medical Center, on Barriers to Multinational Association of Supportive Care in Cancer Guideline Compliance

Dr. Lowell Anthony from the University of Kentucky Markey Cancer Center on Targeted Therapy Associated Diarrhea.

Paul Jacobsen, from H. Lee Moffitt Cancer Center and Research Institute, Discusses Cancer Survivorship Rehabilitation.

Dr. Stuart Lichtman, from Memorial Sloan-Kettering Cancer Center Commack, Explains the Benefits of Supportive and Palliative Care.

Donna Berry, from Dana-Farber Cancer Institute, on Compliance to Oral Cancer Therapies.

Jeffrey Crawford, MD, from Duke University Medical Center, on Managing Febrile Neutropenia.

A compilation of photos from the 2012 combined conferences of the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO).

Dr. Jimmie Holland, from Memorial Sloan-Kettering Cancer Center, on the Stigma Toward Psychosocial Care.

Recent evidence shows that some of the newer molecularly targeted therapies can cause diarrhea, which can lead to dose reductions and alterations.